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MaOBJECTIVES The goal of this study was to assess the clinical impact of optical coherence tomography (OCT) ﬁndings
during percutaneous coronary intervention (PCI).
BACKGROUND OCT provides unprecedented high-deﬁnition visualization of plaque/stent structures during PCI;
however, the impact of OCT ﬁndings on outcome remains undeﬁned.
METHODS In the context of the multicenter CLI-OPCI (Centro per la Lotta contro l’Infarto–Optimisation of Percutaneous
Coronary Intervention) registry, we retrospectively analyzed patients undergoing end-procedural OCT assessment and
compared the ﬁndings with clinical outcomes.
RESULTS A total of 1,002 lesions (832 patients) were assessed. Appropriate OCT assessment was obtained in 98.2% of
cases and revealed suboptimal stent implantation in 31.0% of lesions, with increased incidence in patients experiencing
major adverse cardiac events (MACE) during follow-up (59.2% vs. 26.9%; p < 0.001). In particular, in-stent minimum
lumen area <4.5 mm2 (hazards ratio [HR]: 1.64; p ¼ 0.040), dissection >200 mm at the distal stent edge (HR: 2.54;
p ¼ 0.004), and reference lumen area <4.5 mm2 at either distal (HR: 4.65; p < 0.001) or proximal (HR: 5.73; p < 0.001)
stent edges were independent predictors of MACE. Conversely, in-stent minimum lumen area/mean reference lumen
area <70% (HR: 1.21; p ¼ 0.45), stent malapposition >200 mm (HR: 1.15; p ¼ 0.52), intrastent plaque/thrombus pro-
trusion >500 mm (HR: 1.00; p ¼ 0.99), and dissection >200 mm at the proximal stent edge (HR: 0.83; p ¼ 0.65) were
not associated with worse outcomes. Using multivariable Cox hazard analysis, the presence of at least 1 signiﬁcant
criterion for suboptimal OCT stent deployment was conﬁrmed as an independent predictor of MACE (HR: 3.53; 95%
conﬁdence interval: 2.2 to 5.8; p < 0.001).
CONCLUSIONS Suboptimal stent deployment deﬁned according to speciﬁc quantitative OCT criteria was associated
with an increased risk of MACE during follow-up. (J Am Coll Cardiol Img 2015;8:1297–305) © 2015 by the American
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ABBR EV I A T I ON S
AND ACRONYMS
BMS = bare-metal stent(s)
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
IQR = interquartile range
IVUS = intravascular
ultrasound
MACE = major adverse cardiac
event(s)
MI = myocardial infarction
MLA = minimum lumen area
MSA = minimal stent area
NSTEMI = non–ST-segment
elevation myocardial infarction
OCT = optical coherence
tomography
PCI = percutaneous coronary
intervention
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1298clinical utility of this technique to improve
percutaneous coronary interventions (PCIs)
and clinical outcomes remains to be deﬁned
(1–3).
Recently, the CLI-OPCI (Centro per la Lotta
contro l’Infarto–Optimisation of Percuta-
neous Coronary Intervention) study com-
pared angiography alone versus angiographic
guidance plus OCT guidance for routine PCI
(5). The researchers found that OCT can iden-
tify nonoptimal stent deployment in approx-
imately one-third of cases, thus providing
preliminary evidence of the technique’s clin-
ical utility. Importantly, for the ﬁrst time,
the CLIO-PCI study addressed the question
of how to interpret OCT ﬁndings by setting
speciﬁc quantitative criteria to identify sub-
optimal stent deployment (6).SEE PAGE 1306The aim of the present study was to assess
the impact of these pre-speciﬁed OCT quantitative
criteria on clinical outcomes after PCI. For this pur-
pose, the end-procedural OCT data in a large retro-
spective study (CLI-OCPI II) were evaluated. The
study included 1,002 lesions in 832 patients with a
follow-up length of at least 1 year.
METHODS
STUDY DESIGN. This retrospective multicenter PCI
registry included cases with frequency domain OCT
assessment of stent positioning. All case subjects had
at least 1 OCT assessment of the treated vessel, per-
formed at the end of the procedure, with a sufﬁcient
acquisition length to address the whole length of the
stented segments plus the proximal and distal refer-
ence segments (2,6–8). Indications for periprocedural
OCT assessment and its practical utilization were left
to the operator’s discretion; no formal selection
criteria or treatment strategies (e.g., routinely stent
post-dilation) were prospectively adopted in the
enrolled case samples. For the purposes of this study,
only OCT ﬁndings obtained at the end of the proce-
dure were considered.
All patients provided written informed consent for
the index procedure and for telephone/direct visit
follow-up. Ethical approval was waived because of
the study’s observational retrospective design.
As the primary objective of the study, the impact of
the presence of an OCT-based suboptimal stent
deployment on clinical outcome was explored; the
impact of the individual OCT ﬁndings on outcome was
also appraised. For this purpose, the incidence ofmajor adverse cardiac events (MACE) was a composite
of all-cause mortality, myocardial infarction (MI) not
clearly attributable to a nontarget vessel (including
periprocedural MI deﬁned as creatine kinase-
myocardial band level >3 times the upper limit of
normal), and target lesion revascularization. All out-
comes were deﬁned according to the recommenda-
tions of the Academic Research Consortium (9).
Endpoint adjudication was performed by a central
clinical event committee in a blinded fashion. No
extramural funding was used to support this work,
and the authors were solely responsible for the
design, conduct, and ﬁnal contents of the study.
PATIENTS AND PROCEDURES. Overall, 832 consec-
utive patients in Italy undergoing OCT guidance at
5 experienced and high-volume OCT centers
entered the study. Given the retrospective design,
treatment choices (including stenting technique,
drug-eluting stent [DES] utilization, and additional
pharmacological therapy) were according to local
practice. In particular, OCT guidance during the pro-
cedure was not codiﬁed but left to the operator’s
discretion.
PCIs were performed with standard techniques
and catheters by using a femoral or radial approach.
All patients received unfractionated heparin (a
bolus of 70 IU/kg with additional doses aimed at
achieving an intraprocedural activated clotting time
of 250 to 300 s). All patients were pretreated with
325 mg of aspirin and a loading dose of clopidogrel
600 mg, prasugrel 60 mg, or ticagrelor 180 mg, if
the patient was not already on a maintenance dose.
Unless contraindicated, dual antiplatelet therapy
was recommended for at least 12 months. During
the ﬁrst year after discharge, patients were followed
up by means of scheduled direct visits (generally
at 1 and 6 months) and telephone contacts. In
case of any adverse event or new hospitalization,
source documents were obtained and examined in
detail.
OCT MEASUREMENTS AND DEFINITIONS. OCT was
acquired by means of the frequency domain C7-XR
system or the OPTIS system (both St. Jude Medical,
St. Paul, Minnesota) with a nonocclusive technique
according to a well-standardized method (2,8). OCT
assessment of stent implantation was on the basis of
conventional deﬁnitions reported in expert consensus
OCT documents (2,4,10). The value with maximal
predictive accuracy for outcome was used as a cutoff
point for each variable (Figure 1). In particular, the
following factors were considered signiﬁcant ﬁndings:
1. Edge dissection: the presence of a linear rim of
tissue with a width $200 mm and a clear separation
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1299from the vessel wall or underlying plaque that was
adjacent (<5 mm) to a stent edge (2,6).
2. Reference lumen narrowing: lumen area <4.5 mm2
in the presence of signiﬁcant residual plaque
adjacent to stent endings (6);
3. Malapposition: stent-adjacent vessel lumen dis-
tance >200 mm (6,10,11);
4. In-stent minimum lumen area (MLA) <4.5 mm2 (6);
5. In-stent MLA <70% of the average reference lumen
area;
6. Intrastent plaque/thrombus protrusion: tissue
prolapsing between stent struts extending inside a
circular arc connecting adjacent struts or intra-
luminal mass $500 mm in thickness, with no direct
continuity with the surface of the vessel wall or
highly backscattered luminal protrusion in conti-
nuity with the vessel wall and resulting in signal-
free shadowing (2,10,12).FIGURE 1 OCT Criteria Applied to Address Suboptimal OCT Stent De
(A) Edge dissection (linear rim of tissue with a width $200 mm and a c
adjacent to a stent edge. (B) Intrastent plaque/thrombus protrusion (tis
connecting adjacent struts or intraluminal mass $500 mm in thickness w
backscattered luminal protrusion in continuity with the vessel wall and
rowing (lumen area <4.5 mm2 in the presence of signiﬁcant plaque adjac
lumen distance >200 mm). MLA ¼ minimum lumen area; OCT ¼ opticalDeﬁnition of suboptimal OCT stent deployment
required the presence of at least 1 of the OCT ﬁndings
signiﬁcantly associated with MACE.
By study design, only ﬁnal OCT images performed at
the end of the procedures were analyzed off-line at a
certiﬁed central core laboratory (Rome Heart
Research, Rome, Italy) whose operators were blinded
to procedural characteristics and outcomes.
STATISTICAL ANALYSIS. Continuous variables are
reported as mean  SD or median (1st to 3rd quartile)
in case of normal or skewed distribution; discrete
variables are reported as percentages. The Student t
test, Mann-Whitney U test, chi-square test, and
Fisher exact test were applied for bivariate analyses
when appropriate. The receiver-operating character-
istic curve was used to evaluate the predictive accu-
racy of each OCT parameter for outcome; the highest
Youden index (J statistic) representing the maximumployment
lear separation from the vessel wall or underlying plaque) that was
sue prolapsing between stent struts extending inside a circular arc
ith no direct continuity with the surface of the vessel wall or highly
resulting in signal-free shadowing). (C) Reference (REF) lumen nar-
ent to stent endings). (D) Stent malapposition (stent-adjacent vessel
coherence tomography.
TABLE 1 Patient Cha
Age, yrs
Female
Left ventricular ejectio
Hypertension
Hypercholesterolemia
Smoking habit
Family history of CAD
Diabetes mellitus
CKD (GFR <60 ml/min
Multivessel disease
Prior MI
Prior revascularization
Prior PCI
Prior CABG
Acute coronary syndro
STEMI
NSTEMI
Unstable angina
Stable angina
Values are median (interqu
CABG ¼ coronary artery
glomerular ﬁltration rate; M
segment elevation myoca
elevation myocardial infarc
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1300potential effectiveness was used to determine the
optimal cutoff (13,14). Combined adverse events were
evaluated on a per-patient hierarchical basis; thus,
only 1 hard event per patient per event type was
summarized as Kaplan-Meier estimates.
All study variables were tested for bivariate asso-
ciation with MACE; if nominally signiﬁcant (p < 0.05),
they were simultaneously forced into a Cox regres-
sion model to identify independent outcome pre-
dictors and to calculate their adjusted hazard ratios
(HRs) with associated 95% conﬁdence intervals (CIs).
The Cox regression model included the following
variables: left ventricular ejection fraction, diabetes
mellitus, family history of coronary artery disease,
non–ST-segment elevation myocardial infarction
(NSTEMI) diagnosis, multivessel disease, left main
disease, previous MI, angiographically ambiguous
lesion (i.e., intermediate lesion with irregular contour
and/or haziness), in-stent restenosis lesion, bare-
metal stent (BMS) usage, ostial lesion treatment,
and suboptimal ﬁnal OCT result.
A score quantifying the propensity to incur
MACE was computed to adjust for potential con-
founding factors inherent to the observational nature
of the study (15,16). Speciﬁcally, the individual score,
deﬁned as the conditional probability of experiencing
MACE, was estimated with a nonparsimonious logisticracteristics
All Patients
(N ¼ 832)
Patients
With MACE
(n ¼ 105)
Patients
Without MACE
(n ¼ 727) p Value
64 (56–72) 66 (55–75) 64 (56–72) 0.19
243 (29.2) 25 (23.8) 218 (30.0) 0.21
n fraction 55 (48–60) 52 (43–60) 55 (48–60) 0.002
587 (70.6) 77 (73.3) 510 (70.2) 0.73
510 (61.3) 61 (58.1) 449 (61.8) 0.39
280 (33.7) 37 (35.2) 243 (33.4) 0.82
252 (30.3) 19 (18.1) 233 (32.0) 0.002
179 (21.5) 27 (25.7) 152 (20.9) 0.31
/1.73 m2) 155 (18.6) 23 (21.9) 132 (18.2) 0.21
438 (52.6) 69 (65.7) 369 (50.8) 0.024
164 (19.7) 34 (32.4) 130 (17.9) <0.001
252 (30.3) 29 (27.6) 223 (30.7) 0.50
238 (28.6) 26 (24.8) 212 (29.2) 0.36
31 (3.7) 6 (5.7) 25 (3.4) 0.27
me 469 (56.4) 61 (58.1) 408 (56.1) 0.83
258 (31.0) 31 (29.5) 227 (31.2) 0.73
76 (9.2) 20 (19.1) 56 (7.7) <0.001
135 (16.2) 10 (9.5) 125 (17.2) 0.05
363 (43.6) 44 (41.9) 319 (43.9) 0.83
artile range) or n (%).
bypass graft; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; GFR ¼
I ¼myocardial infarction; MACE¼major adverse cardiac event(s); NSTEMI¼ non–ST-
rdial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
tion.regression model, including all available co-variables
but excluding those that were OCT related (C-statis-
tic: 0.78; 95% CI: 0.71 to 0.85). Adjusted effect esti-
mates were estimated from models in which the score
was entered as covariates. In addition, as a sensitivity
analysis, a matched pair analysis was performed on the
basis of the propensity to develop MACE.
A 2-tailed, p value <0.05 was established as the
level of statistical signiﬁcance for all tests. All statis-
tical analyses were conducted by using SPSS-PASW
version 22.0 (IBM SPSS Statistics, IBM Corporation,
Armonk, New York).
RESULTS
Between 2008 and 2013, a total of 832 patients with
1,002 lesions undergoing post-stenting OCT assess-
ment were included in the registry. Clinical and proce-
dural features of the study population are summarized
in Tables 1 and 2, respectively. The patients’median age
was 64 years (interquartile range [IQR]: 56 to 72 years),
and the study included 29.2% female subjects.
Diagnosis at admission was acute coronary syndrome
in 56.4% of patients, including acute ST-segment
elevation MI in 31.0%. Most of the patients had a
complex lesion proﬁle (Ellis class B2/C 74.8%), with
multivessel disease involvement in 52.6%.
Treated lesion location was as follows: left main,
4.8%; left anterior descending artery, 50.7%; left
circumﬂex artery, 21.4%; right coronary artery, 22.7%;
and graft conduit, 0.4%. DES implantation occurred
in 71.4% of the lesions, and multiple overlapping
stents were implanted in 21.4% of cases. Direct
stenting and high-pressure stent post-dilation rates
were 27.0% and 48.0%, respectively.
All OCT acquisitions were successfully performed;
however, during off-line analysis, 1.8% of cases were
discarded due to insufﬁcient quality images (e.g.,
improper acquisition technique) (6). Therefore, OCT
assessment was analyzed in 984 stented lesions, and
suboptimal stent implantation was noted in 31.0% of
cases (Table 3). In particular, OCT disclosed in-stent
MLA <4.5 mm2 in 23.4% of the stented lesions, edge
dissection in 12.7%, in-stent lumen underexpansion
in 23.7%, malapposition in 49.3%, intrastent plaque/
thrombus protrusion in 29.4%, and reference lumen
narrowing in 7.5%.
The immediate angiographic success rate (residual
stenosis <30% with Thrombolysis In Myocardial
Infarction ﬂow grade 3) was 97.6% with a periproce-
dural MI prevalence of 2.6%. The cumulative MACE
rate at a median follow-up of 319 days (IQR: 123 to 576
days) was 12.6%, with 2.9% all-cause mortality, 7.7%
nonfatal MI, and 6.7% target lesion revascularization
TABLE 2 Procedural Characteristics
All Lesions
(N ¼ 984)
Lesions
With MACE
(n ¼ 125)
Lesions
Without MACE
(n ¼ 859) p Value
Location of lesion treated
Left main 47 (4.8) 12 (9.6) 35 (4.1) 0.012
Left anterior descending artery 499 (50.7) 65 (52.0) 434 (50.5) 0.83
Left circumﬂex artery 211 (21.4) 29 (23.2) 182 (21.2) 0.69
Right coronary artery 223 (22.7) 17 (13.6) 206 (24.0) 0.013
Graft conduit 4 (0.4) 2 (1.6) 2 (0.2) 0.08
Lesion features
Ellis class B2/C 736 (74.8) 89 (71.2) 647 (75.3) 0.91
Calciﬁed lesion 148 (15.0) 18 (14.4) 130 (15.1) 0.85
Ostial lesion 52 (5.3) 11 (8.8) 41 (4.8) 0.048
Bifurcation lesion 138 (14.0) 23 (18.4) 115 (13.4) 0.17
Chronic total occlusion lesion 24 (2.4) 0 (0.0) 24 (2.8) 0.10
Angiographically ambiguous lesion 86 (8.7) 17 (13.6) 69 (8.0) 0.023
In-stent restenosis lesion 37 (3.8) 9 (7.2) 28 (3.3) 0.045
Stent-thrombosis lesion 28 (2.8) 4 (3.2) 24 (2.8) 0.78
Technical approach
Direct stenting 266 (27.0) 33 (26.4) 233 (27.1) 0.98
Thrombectomy use 145 (14.7) 17 (13.6) 128 (14.9) 0.89
Post-dilation 472 (48.0) 51 (40.8) 421 (49.0) 0.24
DES 703 (71.4) 79 (63.2) 624 (72.6) 0.048
BMS 215 (21.9) 43 (34.4) 172 (20.0) 0.002
BVS 66 (6.7) 3 (2.4) 63 (7.4) 0.05
Overlapping stent 211 (21.4) 26 (20.8) 185 (21.5) 0.91
Optimal angiographic result* 960 (97.6) 121 (96.8) 839 (97.7) 0.78
Stent diameter, mm 3.0 (2.75–3.5) 3.0 (2.5–3.0) 3.0 (2.75–3.5) 0.07
Stent length, mm 22 (15–28) 18 (15–28) 22 (15–30) 0.18
Max pressure during stent
implantation
16 (14–18) 16 (14–18) 16 (14–18) 0.24
Contrast dye 250 (200–300) 230 (200–318) 250 (200–300) 0.46
Values are n (%) or median (interquartile range). *Deﬁned as residual stenosis <30% and ﬁnal Thrombolysis In
Myocardial Infarction 3 ﬂow.
BMS ¼ bare-metal stent; BVS ¼ bioresorbable vascular scaffold; DES ¼ drug-eluting stent; MACE ¼ major
adverse cardiac events.
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1301(Table 4). Notably, 82% of adverse events occurred
within the ﬁrst 12 months after the procedure with a
mean time-to-MACE of 26 days (IQR: 1 to 216 days).
MACE PREDICTORS. Compared with patients with
event-free survival, patients with MACE during
follow-up had a lower left ventricular ejection fraction
(52% [IQR: 43% to 60%] vs. 55% [IQR: 48% to 60%];
p¼ 0.002), more frequent NSTEMI diagnosis (19.1% vs.
7.7%; p < 0.001), more prior MI (32.4% vs. 17.9%; p <
0.001), andmoremultivessel disease (65.7% vs. 50.8%;
p ¼ 0.024) (Table 1). Regarding the procedural aspects,
patients with MACE were characterized by higher BMS
use (34.4% vs. 20.0%; p ¼ 0.002) and more frequent
treatment of a left main (9.6% vs. 4.1%; p ¼ 0.012),
ostial (8.8% vs. 4.8%; p ¼ 0.048), angiographically
ambiguous (13.6% vs. 8.0%; p ¼ 0.023), or in-stent
(7.2% vs. 3.3%; p ¼ 0.045) restenosis lesion (Table 2).
OCT analyses revealed a signiﬁcantly higher inci-
dence of suboptimal stent deployment in lesions
associated with any adverse event during follow-up
(59.2% vs. 26.9%; p < 0.001). In particular, patients
with lesions and MACE reported more frequent in-
stent MLA <4.5 mm2 (40.8% vs. 20.8%; p < 0.001),
dissection >200 mm at the distal stent edge (16.0% vs.
5.7%; p < 0.001), and reference lumen area <4.5 mm2
in the presence of residual signiﬁcant plaque at
either the distal (22.4% vs. 3.4%; p<0.001) or proximal
(11.2% vs. 1.2%; p < 0.001) stent edges. Conversely, in-
stent MLA <70% of the average reference lumen area
(30.4% vs. 22.7%; p ¼ 0.07), dissection at the proximal
stent edge (6.4% vs. 6.6%; p ¼ 0.92), malapposition
(50.4% vs. 49.1%; p ¼ 0.85), or in-stent plaque/
thrombus prolapse (30.4% vs. 29.2%; p ¼ 0.83) were
not associated with an increased MACE rate (Table 3).
In the multivariable Cox hazard analysis, subopti-
mal OCT stent deployment was conﬁrmed as an inde-
pendent predictor ofMACE (HR: 3.53; 95%CI: 2.2 to 5.8;
p < 0.001), together with impaired left ventricular
ejection fraction (HR: 2.12; 95%CI: 1.3 to 3.5; p¼0.003),
NSTEMI diagnosis (HR: 1.99; 95% CI: 1.1 to 3.6; p ¼
0.021), and left main disease (HR: 2.79; 95% CI: 1.3 to
6.2; p ¼ 0.012). Figure 2 presents the relative Kaplan-
Meier curves, and Table 5 displays the predictive
value of the individual OCT criteria of suboptimal stent
deployment. Sensitivity analysis on the basis of 146
patients matched for the propensity to incur MACE
conﬁrmed the results stemming from themain analysis
in terms of both statistical direction and magnitude.
DISCUSSION
The main ﬁnding provided by this large multicenter
registry was that patients exhibiting suboptimal stent
deployment on the basis of speciﬁc OCT criteriaexperienced a higher rate of MACE during follow-up.
Indeed, suboptimal stent deployment was signiﬁ-
cantly more common in the MACE group (59.2% vs.
26.9%; p < 0.001) and was found to be an indepen-
dent predictor of MACE.
THE NEW ANGLE OF VIEW. Recent intravascular
ultrasound (IVUS) data derived from observational
studies and large meta-analyses have proven the ef-
ﬁcacy of an IVUS-guided approach for reducing
adverse clinical outcomes (including death, MI, and
stent thrombosis) after PCI (17,18). OCT represents
a new angle of view to address the adequacy of
stent deployment. Besides enabling measurement of
IVUS-validated predictors of MACE (including MLA
and inﬂow/outﬂow disease), the high resolution of
the OCT technique permits detection of features that
may be missed by IVUS, such as malapposition,
intrastent plaque/thrombus protrusion, or dissections
at the stent edges and inside the stents.
TABLE 3 OCT Findings
All Lesions
(N ¼ 984)
Lesion With MACE
(n ¼ 125)
Lesion Without MACE
(n ¼ 859) p Value
OCT features
Minimum in-stent lumen area, mm2 6.0  2.1 5.6  2.1 6.1  2.1 0.025
Maximum in-stent lumen diameter, mm 3.0  0.5 2.9  0.5 3.0  0.5 0.06
Minimum in-stent lumen diameter, mm 2.4  0.5 2.3  0.5 2.4  0.5 0.029
Lumen symmetry, % 1.2  0.2 1.3  0.2 1.2  0.2 0.12
In-stent lumen expansion, %* 85.6  23.1 85.4  28.9 85.7  22.1 0.91
Distal reference lumen area, mm2 6.3  2.8 5.6  2.3 6.4  2.9 0.001
Proximal reference lumen area, mm2 8.2  3.4 7.5  3.2 8.3  3.5 0.016
Malapposition thickness, mm 0.23  0.23 0.25  0.24 0.23  0.22 0.32
Malapposition length, mm 3.4  4.3 3.1  3.7 3.4  4.4 0.45
Intrastent plaque/thrombus protrusion, mm 0.40  0.41 0.46  0.31 0.40  0.42 0.08
Distal edge dissection length, mm 0.23  0.95 0.59  2.09 0.18  0.64 0.05
Distal edge dissection width, mm 0.04  0.13 0.10  0.24 0.03  0.10 0.001
Distal edge dissection arc,  7.5  25.7 20.3  51.4 5.6  18.8 0.003
Proximal edge dissection length, mm 0.13  0.53 0.20  0.85 0.12  0.47 0.33
Proximal edge dissection width, mm 0.03  0.12 0.04  0.13 0.03  0.12 0.49
Proximal edge dissection arc,  5.6  18.3 7.5  21.1 5.3  17.9 0.31
Suboptimal OCT criteria
Minimum in-stent lumen area <4.5 mm2 230 (23.4) 51 (40.8) 179 (20.8) <0.001
In-stent lumen underexpansion† 233 (23.7) 38 (30.4) 195 (22.7) 0.07
Malapposition >200 mm 485 (49.3) 63 (50.4) 422 (49.1) 0.85
Intrastent plaque/thrombus protrusion >500 mm 289 (29.4) 38 (30.4) 251 (29.2) 0.83
Edge dissection >200 mm 125 (12.7) 25 (20.0) 100 (11.6) 0.013
Distal dissection 69 (7.0) 20 (16.0) 49 (5.7) <0.001
Proximal dissection 65 (6.6) 8 (6.4) 57 (6.6) 0.92
Reference narrowing‡ 74 (7.5) 38 (30.4) 36 (4.2) <0.001
Distal narrowing 57 (5.8) 28 (22.4) 29 (3.4) <0.001
Proximal narrowing 24 (2.4) 14 (11.2) 10 (1.2) <0.001
At least 1 predictive OCT criterion§ 305 (31.0) 74 (59.2) 231 (26.9) <0.001
Values are mean  SD or n (%). *Deﬁned as in-stent-to mean reference lumen area. †Deﬁned as in-stent minimum lumen area <70% of the average reference lumen area.
‡Deﬁned as reference lumen area <4.5 mm2 in the presence of signiﬁcant residual plaque adjacent to stent endings. §Including only optical coherence tomography (OCT)
criteria predictive of major adverse cardiac events (MACE) at multivariable analysis.
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1302The multicenter CLI-OPCI registry (5) showed that
OCT could potentially improve the clinical outcomes
after coronary intervention in a real-world popula-
tion. In fact, the 1-year composite of cardiac death or
nonfatal MI was signiﬁcantly lower in the OCT-guidedTABLE 4 Clinical Outcomes
All Patients
(N ¼ 832)
Patients With
Suboptimal OCT Depl
(n ¼ 254)
MACE 105 (12.6) 64 (25.2)
Death 24 (2.9) 11 (4.3)
Myocardial infarction 64 (7.7) 42 (16.5)
Periprocedural 22 (2.6) 11 (4.3)
During follow-up 42 (5.1) 31 (12.2)
Target lesion revascularization 56 (6.7) 42 (16.5)
Stent thrombosis 30 (3.6) 26 (10.2)
Days of follow-up 319 (123–576) 312 (118–584
Values are n (%) or median (interquartile range). *Either in-stent minimum lumen area <
narrowing.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 3.intervention arm. However, the promising con-
clusions reached by the CLI-OPCI registry should
be approached with caution because of its non-
randomized design and relatively small population
size (335 patients in the OCT group).oyment*
Patients With
Optimal OCT Deployment
(n ¼ 578) HR (95% CI) p Value
41 (7.1) 4.41 (2.9–6.8) 0.001
13 (2.2) 1.97 (0.9–4.5) 0.104
22 (3.8) 5.01 (2.9–8.6) 0.001
11 (1.9) 2.33 (1.0–5.5) 0.050
11 (1.9) 7.17 (3.5–14.5) 0.001
14 (2.4) 7.98 (4.3–14.9) 0.001
4 (0.7) 16.36 (5.6–47.4) 0.001
) 324 (129–575) – 0.536
4.5 mm2, dissection >200 mm at the distal stent edge, or distal or proximal reference
FIGURE 2 Clinical Outcomes
Optimal OCT stent deployment
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Survival free of major adverse cardiac events according to optimal versus nonoptimal stent
deployment assessed using optical coherence tomography (OCT).
TABLE 5 Predictive Value of OCT Criteria
HR (95% CI) p Value
Unadjusted
In-stent minimum lumen area <4.5 mm2 2.62 (1.8–3.9) <0.001
Distal dissection >200 mm 3.15 (1.8–5.5) <0.001
Proximal dissection >200 mm 0.96 (0.4–2.1) 0.92
In-stent lumen underexpansion* 1.49 (1.0–2.3) 0.06
Malapposition >200 mm 1.05 (0.7–1.5) 0.79
Intrastent plaque/thrombus protrusion >500 mm 1.06 (0.7–1.6) 0.79
Distal reference narrowing† 8.26 (4.7–14.5) <0.001
Proximal reference narrowing† 10.71 (4.6–24.7) <0.001
Adjusted
In-stent minimum lumen area <4.5 mm2 1.64 (1.1–2.6) 0.040
Distal dissection >200 mm 2.54 (1.3–4.8) 0.004
Proximal dissection >200 mm 0.83 (0.4–1.9) 0.65
In-stent lumen underexpansion* 1.21 (0.7–1.9) 0.45
Malapposition >200 mm 1.15 (0.8–1.7) 0.52
Intrastent plaque/thrombus protrusion >500 mm 1.00 (0.6–1.6) 0.99
Distal reference narrowing† 4.65 (2.5–8.8) <0.001
Proximal reference narrowing† 5.73 (2.2–14.6) <0.001
*Deﬁned as in-stent minimum lumen area <70% of the average reference lumen area. †Deﬁned as reference
lumen area <4.5 mm2 in the presence of signiﬁcant plaque.
OCT ¼ optical coherence tomography; other abbreviations as in Table 4.
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1303The present study broadens the previous experi-
ence of the CLIO-PCI registry by assessing the role of
OCT ﬁndings after PCI in a much larger population
(832 patients and 1,002 lesions; median follow-up 319
days). Consistent with previous data (5), CLI-OPCI II
showed that OCT-deﬁned suboptimal stent deploy-
ment was a relatively common ﬁnding (31.0% of
cases), with a signiﬁcantly higher prevalence in pa-
tients experiencing MACE in the ﬁrst year of follow-up
(59.2% vs. 26.9%; p < 0.001), and was an independent
predictor of worse outcome (HR: 3.53; p < 0.001).
SPECIFIC OCT FINDINGS OF SUBOPTIMAL STENTING.
Conclusions reached by this study are in line with
those emerging from the IVUS substudy of the ADAPT-
DES (Assessment of Dual Antiplatelet Therapy with
Drug Eluting Stents) trial registry (18). In particular,
the CLIO-PCI II highlighted the role of residual refer-
ence segment disease. Stented segments exhibiting a
narrowing at the reference lumen area <4.5 mm2 in
the presence of signiﬁcant plaque experienced a
worse outcome, with the risk of MACE approximately
5 times higher regardless of the location (proximal or
distal reference segment). These data were not un-
expected: a large IVUS-identiﬁed plaque burden at the
stent margins represents a well-known risk factor for
late restenosis and thrombosis (19–21).
Dissections >200 mm at the distal stent edge also
conveyed a higher risk of MACE (HR: 2.54; p ¼ 0.004),
whereas proximal dissections had no clinical impact.
The relationship between distal dissection and
worsened clinical outcome has already been noted in
the CLI-OPCI registry (5). This ﬁnding was also in line
with the ADAPT-DES study conﬁrming the ominous
role of distal dissections regardless of the amount of
luminal narrowing. The negative impact of stent edge
dissection, shown in the present study, was empha-
sized by the early occurrence of cardiac events. The
majority of MACE occurred during the ﬁrst 3 months
after the procedure (Figure 2). Importantly, even at
the applied 200-mm threshold, signiﬁcant dissections
may be missed by using IVUS (22).
There are 2 general approaches to assessing
stent underexpansion. The ﬁrst is using absolute di-
mensions that can be expressed as in-stent MLA or
minimal stent area (MSA); the second is the relative
minimal stent–to–mean reference lumen area per-
centage. Using IVUS, Ziada et al. (23) and Sonoda et al.
(24) showed that the absolute dimension was the
strongest predictor of freedom from adverse events
after BMS or DES implantation. Similarly, an absolute
in-stent MLA <4.5 mm2 according to OCT in the pre-
sent study predicted MACE, whereas the relative cri-
terion of stent–to–mean reference lumen area did not.
Patients with subsequent MACE had a smaller MLAcompared with those with no events; relative stent
expansion was virtually identical in the 2 groups. OCT
measurements are reportedly smaller than IVUS (22);
in keeping with this observation, an in-stent MLA<4.5
mm2 according to OCT in the present study was
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1:
OCT-deﬁned suboptimal stent deployment was a rela-
tively common ﬁnding (31.0% of cases), with a signiﬁ-
cantlyhigherprevalence inpatientsexperiencingMACE in
theﬁrst year of follow-up (59.2%vs. 26.9%; p<0.001).
COMPETENCY IN MEDICAL KNOWLEDGE 2:
Suboptimal OCT stent deployment, deﬁned according
to speciﬁc quantitative OCT criteria, was an indepen-
dent predictor of worse outcome (HR: 3.53; p< 0.001).
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: OCT guidance during PCI allowed
identiﬁcation of patients at increased risk of MACE.
TRANSLATIONAL OUTLOOK 1: The management
and reformability of OCT-deﬁned suboptimal stent
deployment require further investigation.
TRANSLATIONAL OUTLOOK 2: Randomized
studies are needed to assess the clinical impact of OCT
guidance during PCI.
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1304consistent with the IVUS MSA criterion that has been
reported after implantation of second-generation DES
(25). Finally, the in-stent MLA reﬂects both actual
stent underexpansion (i.e., the MSA) and in-stent
plaque/thrombus prolapse. In the present study,
56.4% of patients presented with acute coronary syn-
drome, including acute ST-segment elevation MI in
31.0%; this is a patient population in whom in-stent
plaque/thrombus prolapse has an important impact
on in-stent lumen dimensions, whereas expansion of
the metallic scaffold into a thrombus containing le-
sions is often easier than into a ﬁbrotic lesion in pa-
tients with stable angina.
It has been suggested that acute malapposition
may be associated with reduced re-endothelialization
and increased formation of neointima. However, our
data corroborate IVUS ﬁndings that failed to relate
acute stent vessel wall malapposition with clinical
outcome (26,27). Such conclusions were also in
line with those recently reported from the CLI-THRO
study (28) as well as a report from Im et al. (29). In the
CLIO-THRO study (i.e., an OCT prospective registry
designed to address the mechanism of stent throm-
bosis) (28), patients with subacute stent throm-
bosis more often exhibited stent underexpansion,
stent edge dissection, reference lumen narrowing,
and smaller MSA but no increased frequency of stent
malapposition.
STUDY LIMITATIONS. The main limitation of the
present study was its nonrandomized, retrospective
design. Thus, some evident clinical imbalances were
present in patients experiencing MACE compared
with patients with no events during follow-up. How-
ever, the presence of nonoptimal OCT criteria for stent
deployment was an independent predictor of MACE in
the multivariable Cox hazard analysis. This study
included patients with different clinical conditions
(i.e., patients in stable and acute condition) and
treatment approach (i.e., BMS and DES); the role and
importance of the described OCT ﬁndings could vary
among these categories.
Although all the adopted deﬁnitions of suboptimal
stent deployment were derived from previous IVUS
experiences and OCT consensus documents, the
proposed “clinical” cutoffs reﬂect efforts to delineate
a practical approach to OCT guidance; these need tobe validated in further studies, however. Finally,
although some OCT ﬁndings are clearly associated
with worse outcome, treatment and reformability
remain to be investigated.
CONCLUSIONS
The present large multicenter registry showed that
suboptimal stent deployment on the basis of speciﬁc
OCT criteria was frequent in patients experiencing
MACE in the ﬁrst year of follow-up after stent im-
plantation. In particular, suboptimal OCT stent
deployment was an independent predictor of worse
clinical outcome. These data seem to corroborate the
rationale for an OCT-guided strategy during PCI.
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